/ Lupin Gets USFDA Approval Stocks Up 1.6% ~ Ways2Capital|Stock Tips|Stock Market Tips|Intraday Stock Tips|Stock Trading Tips|NSE BSE Tips

Monday, 23 January 2017

Lupin Limited has informed The Bombay Stock Exchange Ltd., and National Stock Exchange Ltd., through a letter on January 23, 2017 about receiving of final US Food and Drug Administration approval. This intimation was pursuant to the Regulation 30 of the Securities and Exchange Board of India Regulations, 2015.
This USFDA approval was for marketing Paraxetin Extended Release Tablets USP, 12.5 mg, 25 mg and 37.5 mg, which is a generic version of Apotex Technologies Inc’s Paxil CR® tablets, 12.5 mg,  25 mg and 37.5 mg, the letter stated.
Lupin Limited is a pharmaceuticals major, based out of Mumbai and has a current market capitalisation of Rs 66,149.44 crore, being a large-cap stock. The stock has been trading strong with an intraday high made at Rs 1490 per share, up by more than 1.50% during the first few hours of Monday morning.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007
Give a Missed Call for Free Trial - 09699997717